Several years ago, leading VC Marc Andreessen proposed the notion that innovation happens through a process of unbundling and rebundling.
Healthcare is no exception.
Through the micro-specialization of companies, we’ve witnessed a great deal of unbundling in the industry. Now, we’ve begun the process of rebundling.
So, what does this mean for the future of healthcare tech? And how do venture investors leverage this idea to decide which digital health startups deserve funding?
Dr. Vineeta Agarwala is General Partner at Andreessen Horowitz, where she leads investments for the a16z bio and health fund across digital health care delivery, biotech and life sciences tools and diagnostics.
Dr. Agarwala has a special interest in companies leveraging unique datasets to improve healthcare delivery, and she serves on several healthcare portfolio company boards, including Memorial Health, Thyme Care and Waymark.
On this episode of HLTH Matters, Dr. Agarwala joins host Dr. Guatam Gulati to discuss what health payviders are doing to aggregate the best technology for specialty care and how we might integrate such specialized health tech into already complicated workflows.
Dr. Agarwala shares her take on the successes and failures of digital health in the last decade, describing how healthcare tech has been transformative for certain patient populations and why she sees most remote connected wearables as a missed opportunity.
Listen in to understand how the high bar for fundraising is changing the way a16z makes decisions and get Dr. Agarwala’s advice for aspiring founders in healthcare tech.
Connect with Dr. Vineeta Agarwala
Connect with Dr. Guatam Gulati